Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | APP | P05067 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.95 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.95 |
| ▸ | F7 | P08709 | 1/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.63 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.63 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.63 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.63 |
| ▸ | KMO | O15229 | 1/20 | 0.61 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL29585450 | 1.00 | ALDH1A1 (0.95) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL150011 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL29349574 | 0.98 | — | — | |
| Niacin SCHEMBL29396199 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL1433 | 0.98 | — | — | |
| Niacin SCHEMBL28292236 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL3081560 | 0.98 | ALDH1A1 (1.00) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL30844065 | 0.98 | — | — | |
| Niacin SCHEMBL23780926 | 0.95 | ALDH1A1 (0.95) | ALDH1A1APPGAAHCAR3HCAR2 | |
| Niacin SCHEMBL23780929 | 0.95 | ALDH1A1 (0.95) | ALDH1A1APPGAAHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS INC (US) | 2021-03-18 | — | — | US | claimed |
| CN-106613142-B | Positive lotus implantation methods | 贵州绿黑农业开发有限公司 | 2019-08-16 | — | — | CN | claimed |
| CN-110092747-A | Niacin recycling, refining methd and wastewater treatment method in one kind waste water containing niacin | 安徽国星生物化学有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110092684-A | A kind of trace element water-soluble fertilizer and preparation method thereof that can remove plant flower | 杜建 | 2019-08-06 | — | — | CN | claimed |
| CN-109721411-A | A kind of gardening effervesce fertilizer and preparation method thereof | 刘宣 | 2019-05-07 | — | — | CN | claimed |
| CN-108546193-A | A kind of functional form fertilizer of addition vitamin | 张梁 | 2018-09-18 | — | — | CN | claimed |
| CN-108293702-A | A kind of strawberry open field culture method | 河北省农林科学院石家庄果树研究所 | 2018-07-20 | — | — | CN | claimed |
| US-20170211062-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | claimed |
| US-20160002624-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | claimed |
| CN-105040400-A | Improved cashmere oxidation-reduction bleaching method | NINGXIA ZHONGYIN CASHMERE CO LTD | 2015-11-11 | — | — | CN | claimed |
| CN-104557685-A | Method for producing nicotinic acid by using nicotinamide mother solution | TIANJIN HANDEWEI PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | claimed |
| WO-2013173789-A2 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| EP-4056637-B1 | CELLULOSE COMPOSITION AND TABLET | ASAHI CHEMICAL IND (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-111818903-B | Cosmetic or medical material | 松下知识产权经营株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11859180-B2 | Antisense oligonucleotide compositions | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-0717980-A2 | Use of guanidine-imidazole derivatives to assist hair growth stimulation | ATELIER DYNAMIQUE S.r.l. (IT) | 1996-06-26 | — | — | EP | disclosed |
| US-4859567-A | Method of forming high contrast negative images | FUJI PHOTO FILM CO., LTD. (JP) | 1989-08-22 | — | — | US | disclosed |
| US-4293391-A | Cadmium plating baths and methods for electrodepositing bright cadmium deposits | ROHCO, INC. (US) | 1981-10-06 | — | — | US | disclosed |
| US-4270989-A | AN AQUEOUS SOLUTION OF A IONIZABLE CADMIUM COMPOUND, A FREE ACID, AND AN ALKYLENE OXIDE ADDUCT OR A POLYOXYALKYLENE GLYCOL HAVING A PHOSPHATE, CARBOXYLATE, OR ARYL SULFATE GROUP | ROHCO, INC. (US) | 1981-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859180-B2 | Antisense oligonucleotide compositions | UPF1, SNRPA1, HNRNPA1 | ALDH1A1 2215/4885APP 1376/4885GAA 363/4885 |
| US-20210079391-A1 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | UPF1, SNRPA1, HNRNPA1 | ALDH1A1 2215/4885APP 1376/4885GAA 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.